Loading
SH
SeaSpine Holdings Corp Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest, by FEKETE MICHAEL, was filed 02 Sept 2021.
SeaSpine Holdings Corp: what insiders have been doing
SeaSpine Holdings Corp is a Healthcare & Pharma company. Its directors and officers file their transactions with SEC (Form 4). SeaSpine Holdings Corp has had no insider filing for more than a year; the last one goes back to 9 January 2023.
Over the whole record (from 2016), the tally stands at 12 purchases and 26 sales.
These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
363
Thresholds
n/a
Buy Volume
€1M
12 ops. · all time
Sell Volume
€3M
26 ops. · all time
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2021FY ended December 2021 · cache
Income statement
RevenueUS$164.8M
Gross profitUS$98.7M60% margin
Net income-US$46.8M-28.4% margin
Last declaration on 9 January 2023
Declarations363 total
9,700 sharesCommon StockSEC:0001637761-23-000046:1
23,725 sharesCommon StockSEC:0001637761-23-000045:0
82,654 sharesCommon StockSEC:0001637761-23-000041:0
23,993 sharesCommon StockSEC:0001637761-23-000044:0
460,275 sharesCommon StockSEC:0001637761-23-000039:0
102,563 sharesCommon StockSEC:0001637761-23-000032:0
88,592 sharesCommon StockSEC:0001637761-23-000040:0
111,966 sharesCommon StockSEC:0001637761-23-000042:0
333,797 sharesCommon StockSEC:0001637761-23-000031:0
69,628 sharesCommon StockSEC:0001637761-23-000035:0
128,640 sharesCommon StockSEC:0001637761-23-000046:0
20,950 sharesCommon StockSEC:0001637761-23-000033:0
90,951 sharesCommon StockSEC:0001637761-23-000038:0
48,556 sharesCommon StockSEC:0001637761-23-000034:0
131,284 sharesCommon StockSEC:0001637761-23-000036:0
36,056 sharesCommon StockSEC:0001637761-23-000043:0
3,150 shares@ US$8.355.6% of flowCommon StockSEC:0001637761-23-000011:1
3,411 shares@ US$8.354.9% of flowCommon StockSEC:0001637761-23-000013:1
3,108 shares@ US$8.353.3% of flowCommon StockSEC:0001637761-23-000012:1
2,490 shares@ US$8.352.9% of flowCommon StockSEC:0001637761-23-000014:1
7,170 shares@ US$8.352.7% of flowCommon StockSEC:0001637761-23-000008:1
425 shares@ US$8.3521.9% of flowCommon StockSEC:0001637761-23-000010:1
3,281 shares@ US$8.353.1% of flowCommon StockSEC:0001637761-23-000009:1
4,868 sharesCommon StockSEC:0001637761-23-000014:0
5,575 sharesCommon StockSEC:0001637761-23-000009:0
25 of 363 declarations
About SeaSpine Holdings Corp
SeaSpine Holdings Corp. (ticker SPNE) was a US-based medical technology company that traded on the NASDAQ market in the United States. Prior to its merger with Orthofix Medical Inc., SeaSpine focused on spinal surgery, building a business around the design, development, and commercialization of surgical solutions for patients with spinal disorders. The company was headquartered in Carlsbad, California, positioning it within one of the key US medtech clusters for orthopedics and spine devices. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1637761/000163776116000053/spne-2015123110xk.htm?utm_source=openai))
From an operating standpoint, SeaSpine developed a portfolio aimed at the spine surgery value chain. Its product set included spinal implants, biologics, and surgical navigation or procedural support tools. The business model was built to serve surgeons, hospitals, and specialty care facilities with an integrated offering rather than a single-product franchise. This made SeaSpine a focused player in a demanding segment where clinical adoption, product innovation, and surgeon relationships are critical to commercial success. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1637761/000163776116000053/spne-2015123110xk.htm?utm_source=openai))
Read moreShow less
In competitive terms, SeaSpine operated in a crowded global market for spine and orthopedic medical devices, competing against much larger multinational manufacturers. Its strategic niche was its specialization in the spine category and its ability to combine hardware, biologics, and navigation into a broader procedural ecosystem. For investors, this type of profile typically offers exposure to procedure growth and innovation, but also implies high execution risk, pricing pressure, and a need for continuous product refresh. ([sec.gov](https://www.sec.gov/Archives/edgar/data/884624/000095017023019721/ofix-20230331.htm?utm_source=openai))
The most significant recent corporate event was SeaSpine’s merger with Orthofix Medical Inc., which became effective on January 5, 2023. SEC filings state that the transaction was an all-stock merger of equals, creating a broader global spine and orthopedics company. As part of that deal, SeaSpine shareholders received Orthofix shares, and SeaSpine ceased to operate as an independent publicly traded issuer. The SEC Form 4 filings around that period also reflect insider ownership changes tied to the transaction. ([sec.gov](https://www.sec.gov/Archives/edgar/data/884624/000095017023019721/ofix-20230331.htm?utm_source=openai))
For French-speaking investors, the key takeaway is that SeaSpine was a US-listed NASDAQ medtech company with a specialized spine franchise, headquartered in Carlsbad, California, and focused on implants, biologics, and surgical navigation. Its standalone equity story ended with the January 2023 merger, after which its assets and operations were folded into Orthofix. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1637761/000163776116000053/spne-2015123110xk.htm?utm_source=openai))
